Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work
Potential Sciences, supported by UK government backing, is pursuing an AI-driven approach to drug discovery by training machine learning models on synthetically-generated biochemical data rather than relying solely on traditional laboratory research. The approach aims to streamline the time-intensive process of bringing new drugs to market.
Key points
- AI models trained on computer-generated biochemical data
- UK government-backed startup
- Targets acceleration of drug development pipeline
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Wired did the reporting; read the original for the full story.
Read the full story at Wired
